The new approach establishes an opportunity to harness the success of immunotherapies that revolutionized the treatment of childhood leukemias for childhood brain cancers.
BPDCN is an aggressive hematologic malignancy with a historically poor prognosis; VisualDx is a clinical decision support system used by more than 2,300 hospitals, clinics, and me ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback